Statins Slow Liver Disease in HIV/HCV Patients

Article

Having HIV puts patients co-infected with hepatitis C at far higher risk. A Baltimore team looked at using statins to slow the course of the liver disease.

Having HIV puts patients co-infected with hepatitis C at far higher risk. A Baltimore team looked at using statins to slow the course of the liver disease. Researchers at Johns Hopkins University School of Medicine and colleagues looked a cohort of these co-infected patients. Reporting at ID Week 2015, Nouf Almaghlouth, MBBS, MPH reported that of 230 patients in a cohort of 1,366 coinfected patients had similar degrees of cirrhosis but death was more common in non-users of statins (28%) than in patients taking statins (13%).They looked at data from 2001 through 2014.

Among patients without cirrhosis, liver disease progressed in 48% of those not taking statins but in only 15% of those taking statins.

"Although statin use was uncommon in our cohort, statins were associated significantly lower incidenceof liver disease," the authors wrote in an abstract. "Statins should be strongly considered in coinfected patients with indications for their use," they concluded.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.